Recruiting
Phase 1

PS & 64Cu-PS

Sponsor:

University Health Network, Toronto

Code:

NCT06977126

Conditions

Gynecological Cancers

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

PORPHYSOMES

64Cu-PORPHYSOMES

Study Details

Brief summary:

This is an open-label, first-in-human, dose escalation study evaluating investigational drug PORPHYSOSMES (PS, pegylated porphyrin-lipid conjugate-containing nanoparticle suspension) and 64Cu-PORPHYSOMES (64Cu-PS, pegylated Copper-64 labelled porphyrin-lipid conjugate-containing nanoparticle suspension) for PET/CT imaging assessments in patients with metastatic/advanced gynecological tumors.

Conditions

Gynecological Cancers

Study ID

NCT06977126

Start date

Nov 18, 2025

Status verified date

Jan, 2026

Completion date

Nov 19, 2027

Anticipated

Primary completion date

Nov 18, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Female patients age ≥ 18 years.
  • Life expectancy of >3 months.
  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
  • Histologically confirmed metastatic advanced gynecological cancer. All epithelial subtypes are permitted. Patients receiving standard of care oncological treatment (i.e. chemotherapy and/or radiation) will be included.
  • Patient is able to understand and is willing to sign a written informed consent document prior to registration/enrollment on to study.
  • Patient is willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
  • Patients of childbearing potential (as assessed by their local Investigator) and their partners who are sexually active must agree to the use of 2 highly effective forms of contraception throughout the period of study treatment and for 12 months after last dose of study drug.
  • Baseline corrected QT (QTc) interval prolongation < 470 milliseconds.
  • Within 8 days of the proposed enrollment patients must have adequate organ function.

Exclusion Criteria:

  • Patient is a candidate for therapy with curative intent.
  • Patient has a contraindication to PET/CT imaging, including, but not limited to, phobias associated with imaging (e.g. claustrophobia) and those who cannot lie still in the supine position for at least 20 minutes.
  • Patients receiving nuclear medicine scans with other radiopharmaceutical agents (ex: 18F-FDG or other) during the study's exclusionary period will be excluded from the study.
  • Patients with known myelodysplastic syndrome/acute myeloid leukemia.
  • Treatment with an investigational drug within 15 days prior to study registration.
  • Patients must not receive any other oncological treatments, including chemotherapy and/or radiation, within 2 weeks before starting study drug administration (and for 28 days after study drug administration).
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in study.
  • Patients with a known active COVID-19 infection at the time of registration/enrollment.
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the Investigator would make the subject inappropriate for entry into this study.
  • Uncontrolled inter-current illness including, but not limited to, ongoing or active infection requiring IV antibiotics, symptomatic congestive heart failure, unstable angina pectoris, unstable cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant or breast-feeding women.
  • Unresolved toxicity > CTCAE grade 1 from previous anti-cancer therapies, including radiotherapy, with exception.
  • Retinopathy ≥ grade 2.
  • Patients with porphyria.
  • Patients that have undergone a splenectomy.

Study Design

Enrollment

24 participants

Anticipated

Intervention Model

Single group

Primary purpose

Diagnostic

Interventions and Outcome Measures

Arms

experimental: PORPHYSOMES and 64Cu-PORPHYSOMES (64Cu-PS)

Participants will receive one dose of 64Cu-PS with one dose of unlabelled PS (except for cohort 1) by intravenous (IV) route on Day 1.

Interventions

PORPHYSOMES

Pegylated porphyrin-lipid conjugate-containing nanoparticle suspension

64Cu-PORPHYSOMES

Pegylated Copper-64 labelled porphyrin-lipid conjugate-containing nanoparticle suspension

Primary outcome measure

  • Incidence of Dose Limiting Toxicities (DLTs) [ Time Frame: 1 year ]

Central Contacts and Locations

Central contacts

Stephanie Lheureux, MD

416-946-2818stephanie.lheureux@uhn.ca

Locations

Princess Margaret Cancer Centre

Recruiting

Toronto, Ontario, Canada, M5G 2M9

Principal Investigator:

Stephanie Lheureux, MD

More Information

Sponsor

University Health Network, Toronto

Last update posted

Jan 8, 2026

Last verified

Jan, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University Health Network, Toronto on 2026-01-08.